Results 171 to 180 of about 2,108 (191)

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy

Drug Design, Development and Therapy, 2022
Paul Sternberg
exaly  

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration

Journal of Clinical Medicine, 2023
Akiko Miki, Wataru Matsumiya, Hisanori Imai   +2 more
exaly  

Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Gabriela Grimaldi, Giuseppe Cancian
exaly  

From Bench to Bedside: Faricimab Enters the Clinic

Ophthalmic Surgery, Lasers and Imaging Retina, 2022
Cecilia Villanueva, Boone, Charles C, Wykoff, Howard F, Fine   +2 more
openaire   +2 more sources

Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Keiko K Kataoka, Kanako Itagaki, Ryo Mukai   +2 more
exaly  

Aflibercept/faricimab

Reactions Weekly, 2023
openaire   +1 more source

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials

Graefe's Archive for Clinical and Experimental Ophthalmology, 2023
Kanji Takahashi, Yasuo Yanagi, Won Ki Lee   +2 more
exaly  

Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases

Expert Opinion on Investigational Drugs, 2021
Massimo Nicolo, Lorenzo Ferro Desideri, Aldo Vagge   +2 more
exaly  

Faricimab for treatment of diabetic macular oedema

Practical Diabetes, 2022
openaire   +1 more source

Aflibercept/faricimab

Reactions Weekly
openaire   +2 more sources